Technical Analysis for KZIA - Kazia Therapeutics Limited - American Depositary Shares

Grade Last Price % Change Price Change
grade C 2.71 -3.56% -0.10
KZIA closed down 3.56 percent on Wednesday, January 16, 2019, on 47 percent of normal volume. It was able to find support at its 50 day moving average.

Earnings due: Jan 23

1 Watcher
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical KZIA trend table...

Date Alert Name Type % Chg
Jan 16 Bearish Engulfing Bearish 0.00%
Jan 16 50 DMA Support Bullish 0.00%
Jan 16 Slingshot Bullish Bullish Swing Setup 0.00%
Jan 16 Upper Bollinger Band Touch Strength 0.00%
Jan 15 Shooting Star Candlestick Bearish -3.56%
Jan 15 Lizard Bearish Bearish Day Trade Setup -3.56%
Jan 15 Crossed Above 50 DMA Bullish -3.56%
Jan 15 New Uptrend Bullish -3.56%
Jan 15 Expansion Pivot Buy Setup Bullish Swing Setup -3.56%
Jan 15 Pocket Pivot Bullish Swing Setup -3.56%

Older signals for KZIA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:
Profile
Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
Is KZIA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Oct 29 Edison issues ADR update on Kazia Therapeutics (KZIA)
Oct 29 Progress Update on GDC-0084 Program
Oct 22 Kazia Enters Clinical Collaboration to Investigate Use of Brain Cancer Drug GDC-0084 in Breast Cancer
Oct 10 Cantrixil Phase I Study Progresses To Next Stage
Oct 1 John Theurer Cancer Center Enrolls First Two Patients Nationwide for Groundbreaking Phase II Clinical Trial for Glioblastoma
Jul 17 Kazia Therapeutics (KZIA) Investor Presentation - Slideshow
See more KZIA news...
Indicators
Indicator Value
52 Week High 6.68
52 Week Low 2.04
Average Volume 3,649
200-Day Moving Average 3.7775
50-Day Moving Average 2.5937
20-Day Moving Average 2.4279
10-Day Moving Average 2.438
Average True Range 0.2607
ADX 25.64
+DI 33.7863
-DI 24.5472
Chandelier Exit (Long, 3 ATRs ) 2.5779
Chandelier Exit (Short, 3 ATRs ) 2.8921
Upper Bollinger Band 2.7765
Lower Bollinger Band 2.0793
Percent B (%b) 0.9
BandWidth 28.716174
MACD Line -0.0161
MACD Signal Line -0.0711
MACD Histogram 0.055
Fundamentals Value
Market Cap 13.09 Million
Num Shares 4.83 Million
EPS -1.80
Price-to-Earnings (P/E) Ratio -1.51
Price-to-Sales 2.05
Price-to-Book 0.71
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.36
Resistance 3 (R3) 3.38 3.18 3.25
Resistance 2 (R2) 3.18 3.02 3.17 3.21
Resistance 1 (R1) 2.95 2.92 2.85 2.93 3.18
Pivot Point 2.75 2.75 2.71 2.74 2.75
Support 1 (S1) 2.52 2.59 2.42 2.50 2.24
Support 2 (S2) 2.32 2.49 2.31 2.21
Support 3 (S3) 2.09 2.32 2.17
Support 4 (S4) 2.07